Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139282 | 0.93 | ACHE (0.49) | ACHEOPRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL7149783 | 0.90 | ACHE (0.54) | ACHEOPRM1SIGMAR1CHRM3CHRM2 | |
| SCHEMBL7167171 | 0.89 | ALDH1A1 (0.48) | ACHEOPRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL7251853 | 0.89 | CHRM3 (0.45) | ACHEOPRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL7190540 | 0.88 | CHRM3 (0.46) | ACHEOPRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL7257804 | 0.87 | CHRM2 (0.43) | ACHEOPRM1CHRM3CACNA1BCHRM4 | |
| SCHEMBL7257336 | 0.87 | CHRM3 (0.44) | ACHEOPRM1CHRM3CHRM4CHRM2 | |
| SCHEMBL7164480 | 0.86 | ACHE (0.55) | ACHEOPRM1SIGMAR1CHRM3CHRM2 | |
| SCHEMBL7256616 | 0.85 | CYP3A4 (0.50) | ACHEOPRM1CHRM3CACNA1BCHRM2 | |
| SCHEMBL7142524 | 0.84 | CHRM2 (0.49) | ACHEOPRM1SIGMAR1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | claimed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | ACHE 826/4885OPRM1 242/4885SIGMAR1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.